Clover Biopharmaceuticals Reports Positive Early Data for Combination Respiratory Vaccine Candidates

Clover Biopharmaceuticals Reports Positive Early Data for Combination Respiratory Vaccine Candidates

By, Admin 16 October 2025

Clover Biopharmaceuticals, Ltd., a global commercial-stage biotechnology company focused on developing innovative vaccines, has announced positive preliminary results from two ongoing phase I clinical trials evaluating its combination respiratory PreF vaccine candidates—SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3)—based on the company’s Trimer-Tag platform technology.

The trials aim to address key gaps in current respiratory syncytial virus (RSV) vaccination by expanding protection to additional respiratory viruses and enabling effective re-vaccination strategies in older adults.

Promising Results from Australian Phase I Trial

In the Australian trial, 144 older adults aged 60–85 were randomized to receive one of three vaccines: SCB-1022, SCB-1033, or the RSV-only comparator SCB-1019.

Key findings include:

  • RSV immune responses: Both SCB-1022 and SCB-1033 generated approximately 6–8-fold increases in RSV-A and RSV-B neutralizing antibodies (nAbs), comparable to SCB-1019.

  • No immune interference: The addition of hMPV and PIV3 antigens did not diminish RSV immune responses.
  • hMPV responses: Participants receiving SCB-1022 and SCB-1033 showed 6–9-fold increases in hMPV-A and hMPV-B nAbs.
  • PIV3 responses: SCB-1033 induced around 4-fold increases in total PIV3 nAbs, and up to 10-fold increases in PIV3 PreF-specific antibodies.
  • Safety: Both combination vaccines were generally well-tolerated, with mild local and systemic adverse events comparable to SCB-1019. No vaccine-related serious adverse events were observed.

Clover plans to advance SCB-1022 and SCB-1033 into phase II clinical trials in the first half of 2026.

U.S. Re-Vaccination Study Shows Stronger Response Than GSK’s Arexvy

A separate U.S.-based phase I study is evaluating re-vaccination potential in older adults who previously received GSK’s Arexvy RSV vaccine at least two seasons earlier. Participants were randomized to receive SCB-1019, Arexvy, or placebo.

Interim results from 34 participants show:

  • SCB-1019 induced 1.6–1.8× higher geometric mean fold rises (GMFRs) in RSV-A and RSV-B nAbs compared with Arexvy.
  • 69–75% of participants receiving SCB-1019 achieved ≥2-fold increases in nAbs, compared with 33–40% for Arexvy.
  • Baseline antibody levels and demographic characteristics were balanced between groups.

These results suggest SCB-1019 may restore and enhance waning RSV protection, offering potential advantages over existing re-vaccination strategies. Additional data from this trial are expected in the first half of 2026.

Addressing Unmet Needs in Respiratory Disease Prevention

Clover’s combination vaccine approach targets RSV, human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3)—three major viral causes of respiratory illness in older adults. Currently approved RSV vaccines are not designed to prevent infections caused by hMPV or PIV3 and lack robust re-vaccination solutions as immunity wanes.

“While currently approved RSV vaccines are safe and effective, significant unmet needs remain,” said Joshua Liang, CEO of Clover Biopharmaceuticals. “Our combination vaccine candidates have the potential to broaden protection and restore waning immunity in older adults.”

Expanding the Trimer-Tag Platform

The company’s Trimer-Tag technology underpins its vaccine candidates, allowing precise stabilization of viral fusion proteins in their prefusion form to elicit strong and targeted immune responses.

The new data reinforce Clover’s plans to build a first-in-class and best-in-class respiratory vaccine franchise. The company expects to progress its combination vaccine candidates into phase II trials by mid-2026

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!